(Q79972618)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Li Wang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Jie Ma

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Fenghua Liu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Qingkai Yu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Guangmin Chu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Yong Li

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

21 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

695-702

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Reproductive and dietary risk factors for epithelial ovarian cancer in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Ovarian cancer metastasis: integrating insights from disparate model organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Mucins in cancer: protection and control of the cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Production and characterization of an anti-(MUC1 mucin) recombinant diabody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

MUC1: the polymorphic appearance of a human mucin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Overexpression of MUC1 reconfigures the binding properties of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

MUC1 immunobiology: from discovery to clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Prognostic significance of MUC1 epithelial mucin expression in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.004

10.1016/J.YGYNO.2007.02.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17368732%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference